This study is a prospective accuracy observational study to evaluate the performance of the Highplex System SARS-Cov-2, Influenza and RSV 8-well in vitro diagnostic medical device panel and generate performance data. The precision of results will be evaluated in concordance with the comparator predicate device panel BioFire Respiratory Panel 2.1 (RP2.1).

开始日期2023-07-01

申办/合作机构

AusDiagnostics Pty Ltd.

DRKS00027129 / RecruitingN/A

Collection of blood samples for the evaluation of the analytical performance of two new in vitro test systems for tuberculosis diagnostics - TID-2

开始日期2022-05-17

申办/合作机构

R-Biopharm AG

100 项与 R-Biopharm AG 相关的临床结果

登录后查看更多信息

0 项与 R-Biopharm AG 相关的专利（医药）

登录后查看更多信息

项与 R-Biopharm AG 相关的文献（医药）

2022-09-06·Journal of AOAC International4区 · 农林科学

Analysis of Aflatoxins, Fumonisins, Deoxynivalenol, Ochratoxin A, Zearalenone, HT-2, and T-2 Toxins in Animal Feed by LC–MS/MS Using Cleanup with a Multi-Antibody Immunoaffinity Column

4区 · 农林科学

Article

作者: Mackay, Naomi ; Leeman, Dave ; Marley, Elaine ; Donnelly, Carol ; Poplawski, Cezary

Abstract:

Background:

Regulations limiting aflatoxin levels in animal feed and guidance values for maximum levels for fumonisins (FB1 and FB2), deoxynivalenol (DON), ochratoxin A (OTA), zearalenone (ZON), HT-2, and T-2 toxins are in place both to protect animal health and to minimize potential transfer to animal products for human consumption. A multi-mycotoxin method which can handle complex feed matrices such as distillers dried grains with solubles (DDGS) is essential for analysis and accurate quantification without the need to revert to separately analyze individual mycotoxins.

Objective:

The objective of this study is to generate single laboratory validation data for a method employing a multi-antibody immunoaffinity column (IAC) capable of providing cleanup for eleven mycotoxins, followed by LC–MS/MS quantification without the need for isotopic labelled and matrix-matched standards. The applicability of method is to be demonstrated for corn feed, pig feed, and DDGS by fortification and naturally occurring mycotoxins covering the range of regulated limits.

Methods:

Feed sample (1 kg) ground by milling to approximately 1–2 mm particle size and sub-sample (5 g) extracted with acetonitrile–water–formic acid, passing through a multi-mycotoxin IAC, washing, and eluting prior to LC–MS/MS analysis monitoring selected ion transitions.

Results:

Recoveries were in the range 74 to 117% (excluding five outliers) for aflatoxins, FB1, FB2, DON, OTA, ZON, HT-2, and T2- toxins spiked into three commercial animal feed matrixes (n = 84) and within-day RSDs averaged 1.7 to 10.3% (n = 99).

Conclusion:

Single laboratory validation of a multi-antibody IAC method coupled with LC–MS/MS has shown the method to be suitable for accurate quantification of eleven regulated mycotoxins in DDGS, pig feed, and poultry feed.

Highlights:

IAC method capable of accurately quantifying eleven regulated mycotoxins in complex feed matrices.

2021-06-12·Journal of AOAC International4区 · 农林科学

Determination of Aflatoxin M1 in Liquid Milk, Cheese, and Selected Milk Proteins by Automated Online Immunoaffinity Cleanup with Liquid Chromatography‒Fluorescence Detection

4区 · 农林科学

Article

作者: Pazdanska, Monika ; Rhemrev, Ria ; Gill, Brendon D ; Marley, Elaine ; Mackay, Naomi ; Wood, Jackie E ; Indyk, Harvey E

Abstract:

Background:

Aflatoxins are secondary metabolites produced by a number of species of Aspergillus fungi. Aflatoxin M1 (AFM1) is a hydroxylated metabolite of aflatoxin B1 and is found in the milk of cows fed with feed spoilt by Aspergillus species. AFM1 is carcinogenic, especially in the liver and kidneys, and mutagenic, and is also an immunosuppressant in humans.

Objective:

A high-throughput method for the quantitative analysis of AFM1 that is applicable to liquid milk, cheese, milk protein concentrate (MPC), whey protein concentrate (WPC), whey protein isolate (WPI), and whey powder (WP) was developed and validated.

Method:

AFM1 in cheese, milk, and protein products is extracted using 1% acetic acid in acetonitrile with citrate salts. The AFM1 in the resulting extract is concentrated using RIDA®CREST/IMMUNOPREP® ONLINE cartridges followed by quantification by HPLC‒fluorescence.

Results:

The method was shown to be accurate for WP, WPC, WPI, MPC, liquid milk, and cheese, with acceptable recovery (81–112%) from spiked samples. Acceptable precision for WP, WPC, WPI, MPC, liquid milk, and cheese was confirmed, with repeatabilities of 4–12% RSD and intermediate precisions of 5–13% RSD. Method detection limit and ruggedness experiments further demonstrated the suitability of this method for routine compliance testing. An international proficiency scheme (FAPAS) cheese sample showed that this method gave results that were comparable with those from other methods.

Conclusions:

A method for high-throughput, routine testing of AFM1 is described. The method was subjected to single-laboratory validation and was found to be accurate, precise, and fit-for-purpose.

Highlights:

An automated online immunoaffinity cleanup HPLC‒fluorescence method for milk proteins, cheese, and milk was developed and single-laboratory validated. It allows for high-throughput analysis of AFM1 and can be used for the analysis of AFM1 in whey protein products.

2020-12-01·Pathology

Rapid deployment of pathology services to a remote Australian quarantine setting during the COVID-19 pandemic

Letter

作者: Poljak, Marin ; Stephens, Dianne ; Polkinghorne, Adam ; Branley, James ; O'Sullivan, Matthew

In early Feb.2020, like other nations, the Australian government launched a mission to retrieve Australian citizens from Wuhan, China, caught up in the travel restrictions imposed in the Hubei province.The mission retrieved 278 Australian citizens to Christmas Island, Australia, to undergo quarantine for 14 days.Christmas Island is an Australian external ter-ritory situated in the Indian Ocean, 1500 km west of the Australian mainland.Evacuees were housed in a government facility with essential health care capability for the duration of the quarantine period.The evacuees remained on Christmas Island for a 14 day quarantine period, prior to return by air to the Australian mainland.In this correspondence we highlight the ability to implement advanced testing in a remote environment.

项与 R-Biopharm AG 相关的新闻（医药）

2024-07-05

·医药观澜

同源不同命！作为GLP-1的“姐妹”，它却被开发治疗这些疾病

▎药明康德内容团队报道 1982年，麻省总医院的几位科学家在《美国国家科学院院刊》（PNAS）发表了一篇论文，他们发现胰高血糖素前体基因实际上编码了三种多肽——胰高血糖素，以及两种在肠道中表达的新型激素[1]。 1年后，科学家们在《自然》（Nature）期刊发表了两篇论文[2][3]，他们从哺乳动物和人类中克隆了胰高血糖素前体基因，并对其进行了酶切分析和序列测定，将这两种在肠道中表达的新型激素命名为胰高血糖素样肽-1（GLP-1）和胰高血糖素样肽-2（GLP-2）。如今，GLP-1和GLP-2在医药研发、临床应用和大众认知中的知名度可谓是“天差地别”，相比于GLP-1的火热，GLP-2略显冷清。同源的GLP-1和GLP-2命运为何如此不同？GLP-2是否被低估？又有哪些医药公司正在关注和投入资源研发GLP-2，以发掘其在医学领域的潜力？今天，我们将结合公开资料，带大家了解下GLP-2这个肽类激素。图片来源：123RF “同源不同命”的GLP-1和GLP-2 尽管可以将GLP-1和GLP-2称为“同源姐妹”，但是两者的生理功能却各不相同，甚至在某些方面完全相反。 GLP-1与其受体结合后，通过葡萄糖浓度依赖的方式刺激胰岛素合成和分泌，减少胰高血糖素的分泌。同时，它还能作用于中枢神经系统的GLP-1受体，抑制食欲，减少进食量，延缓食物从胃到小肠的速度，增加饱腹感，从而达到降低血糖和减重的作用。 GLP-2的主要功能是刺激肠粘膜隐窝细胞的增殖和抑制其凋亡，从而促进肠粘膜的生长及损伤后的再生修复，还可以抑制胃酸分泌和胃的运动，增加肠道血液供应，提高肠道的屏障功能，促进肠道对营养物质的吸收等。 GLP-1和GLP-2对血糖浓度的影响可谓是完全相反。GLP-1可以抑制胰高血糖素分泌，降低血糖；而GLP-2能够增加血糖，并且促进肠道生长。作用机制的不同，也使GLP-1和GLP-2相关药物的治疗领域截然不同：GLP-1在降糖、减重等领域大放异彩；而GLP-2则在肠道疾病领域不断取得新进展。 “低调的肠道守护者” GLP-2是一个低调但极其重要的肠道“守护者”，尽管其在医学界的知名度不及GLP-1，但GLP-2在维持肠道健康和治疗特定肠道疾病方面发挥着不可或缺的作用。在肠道内，GLP-2的释放主要是为了响应营养素的摄入，以促进这些营养素的吸收和加工。例如，GLP-2可以通过刺激肠道细胞的己糖和肽转运载体的表达或者活性来增加营养吸收；可以增强麦芽糖酶-糖化酶和蔗糖酶-异麦芽糖酶的表达，而这些酶是消化淀粉和其他糖类以及参与肽类消化的氨基肽酶N所必需的；此外，它还可以影响脂肪酸移位酶，增加肠道对脂类的吸收等。图片来源：123RF GLP-2还可以降低胃排空、胃酸分泌和肠道蠕动，促进肠道对营养物质的有效吸收。有研究发现，GLP-2可以通过增殖肠道上皮细胞、隐窝细胞和减少细胞凋亡来扩大营养吸收的区域和能力。动物实验还表明，对于特定发育阶段和肠道损伤状况，GLP-2还表现出保护肠黏膜免受炎症和促进肠道损伤后的修复功能，以及提高肠道屏障功能的作用。在肠道外，GLP-2的作用则主要集中在胰腺、骨骼和中枢神经系统，比如：它可以刺激胰高血糖素的释放；增加脊椎骨密度，改善肠道钙离子吸收；产生饱腹感抑制食物摄入、维持细胞存活、减少肠道蠕动性和降低血压等。首款GLP-2类药物已获批 GLP-2相关药物主要应用于治疗肠道疾病或改善处于不良状况的肠道营养吸收，比如短肠综合征（SBS）、炎症性肠道疾病、结肠炎或结肠损伤、肠缺血、坏死性结肠炎（尤其早产儿）、全肠外营养诱导的肠道萎缩，以及因化疗、放疗、长期使用非类固醇消炎药和病原体引起的肠炎肠道屏障功能损伤等。目前，全球首款GLP-2类药物——替度格鲁肽（teduglutide）已经获批上市。替度格鲁肽是武田（Takeda）公司研发的一款GLP-2类似物。天然GLP-2的半衰期只有7分钟，替度格鲁肽的半衰期大约1.3小时，临床推荐每日皮下注射一次。该药最早于2012年在欧盟获批上市，随后在美国、日本相继获得批准。此外，替度格鲁肽皮下注射制剂也曾获FDA孤儿药资格。 2024年2月，替度格鲁肽正式获得中国国家药品监督管理局（NMPA）批准，适用于治疗短肠综合征（SBS）成人和1岁及以上儿童患者。患者应仅在经过一段时间肠道适应后，在病情稳定且依赖肠外营养支持的情况下使用该产品治疗。短肠综合征是一种罕见病，已被纳入中国《第二批罕见病目录》。该病是指因各种原因引起广泛小肠切除或旷置后，肠道有效吸收面积显著减少，残存的功能性肠管不能维持患者的营养或儿童生长需求，并出现以腹泻、酸碱／水／电解质紊乱、以及各种营养物质吸收及代谢障碍为主的症候群。作为一款肠康复创新药，替度格鲁肽可帮助剩余的肠道吸收更多的营养，减少肠外营养的频率和容量。研究发现，替度格鲁肽可以增加绒毛高度及隐窝深度，加强肠道上皮屏障，从而减轻局部炎症并改善肠道通透性，促进肠适应。全球临床阶段的在研GLP-2药物尽管目前GLP-2的应用范围有限，但一些医药公司已经开始关注并投入资源研发GLP-2类药物，以探索其在医学领域的潜力。公开资料显示，除替度格鲁肽外，全球目前在研的GLP-2药物有近20款，其中有8款处于临床阶段。从适应症来看，这些在研药物主要针对肠道疾病，如短肠综合征、克罗恩病、腹泻等；少数GLP-1和GLP-2双靶点药物用于治疗2型糖尿病或肥胖症。 *本表由《医药观澜》根据公开资料整理，如有遗漏，欢迎补充。以下将介绍部分进入临床阶段的在研GLP-2药物信息，仅供读者参阅。 Zealand Pharma公司：glepaglutide、elsiglutide、dapiglutide Glepaglutide是一款长效GLP-2药物，其半衰期更长，10 mg剂量用药皮下注射可实现每周一次/两次用药。Glepaglutide已于2023年12月向FDA提交上市申请，用于治疗依赖肠外支持治疗的短肠综合征成人患者。而且该药物已获得FDA授予孤儿药资格。此外，glepaglutide用于治疗克罗恩病的适应症已处于临床试验1期。 Elsiglutide是Zealand Pharma公司研发的另一款GLP-2类似物，拟用于治疗化疗引起的腹泻，目前已处于临床试验2期。动物实验发现，elsiglutide可增加细胞增殖并减少肠道凋亡，减少帕拉替尼治疗引起的腹泻。此外，Zealand Pharma公司还开发了一款在研的GLP-1和GLP-2受体双激动剂——dapiglutide。Dapiglutide是一种潜在“first-in-class”的长效肽疗法，旨在利用强效GLP-1激动剂的效果来减重，并通过GLP-2的肠道屏障改善功能来解决与低级别炎症相关的并发症。目前，该药治疗肥胖适应症的临床试验已处于2期阶段，其治疗短肠综合征适应症的临床试验已处于1期阶段。 Ironwood公司：apraglutide Apraglutide（阿帕拉格鲁肽）是Ironwood Pharmaceuticals公司通过收购VectivBio公司获得的一种新一代、人工合成的长效GLP-2类似物，拟开发用于一系列GLP-2在疾病病理生理学中可以发挥中心作用的罕见胃肠疾病。目前，该药治疗短肠综合征的临床试验也已进入3期阶段；治疗胃肠道急性移植物抗宿主病的临床试验已进入2期阶段。韩美制药：HM15912 据韩美制药新闻稿介绍，HM15912是该公司研发的一种长效GLP-2类似物，可通过非肽基柔性连接子与人免疫球蛋白恒定区化学偶联，有望实现每月注射一次。目前，该药治疗短肠综合征的临床试验也已进入2期阶段。除了上述已进入2期临床及其以上研发阶段的药物，还有几款GLP-2靶向药物已获批或进入1期临床，包括：艾伯维（AbbVie）的长效GLP-2R激动剂CLF065，正在开展针对炎症性肠病的1期临床；派金生物的重组酰化GLP-2类似物PJ020，已于今年在中国获批临床，拟用于治疗化疗相关性腹泻；Progen公司的GLP-1和GLP-2双靶点药物PG-102，正在开展治疗肥胖适应症的1期临床试验。未来与展望尽管目前GLP-2类药物的应用范围有限，但其在肠道健康中的重要作用使得它具有广阔的应用前景。未来，随着研究的深入，GLP-2类药物也可能在治疗其他肠道疾病，如炎症性肠病（如克罗恩病和溃疡性结肠炎）中发挥更大的作用。此外，随着对肠道健康重要性的进一步认识，GLP-2类药物有望在未来获得更多的关注和应用，发挥更大的医学价值，为更多患者带来希望和治疗选择。参考资料：（可上下滑动查看） [1] P K Lund,et al.,(1982).Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proceedings of the National Academy of Sciences of the United States of America,DOI:10.1073/pnas.79.2.345. [2] Graeme I. Bell,et al.,(1983).Hamster preproglucagon contains the sequence of glucagon and two related peptides.Nature,DOI:10.1038/302716a0. [3] Graeme I. Bell,et al.,(1983).Exon duplication and divergence in the human preproglucagon gene.Nature,DOI:10.1038/304368a0. [4] Sara Baldassano,et al.,(2014).GLP-2:What do we know? What are we going to discover?.Regulatory peptides,DOI:10.1016/j.regpep.2014.09.002. [5] P. Janssen,et al.,(2012).Review article: a comparison of glucagon‐like peptides 1 and 2. Alimentary pharmacology & therapeutics,DOI:10.1111/apt.12092. [6] 李幼生,等（2017）.中国短肠综合征诊疗共识(2016年版).中华医学杂志,DOI:10.3760/cmaj.issn.0376-2491.2017.08.003. [7] HOW DO GLP-2 ANALOGS WORK?.Retrieved Jul 3,2024,from https://www.rxlist.com/how_do_glp-2_analogs_work/drug-class.html 本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床结果

2024-06-24

·BioSpace

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill®capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and ProGen to share responsibilities for the development and commercialization of RT-114, including a 50/50 cost and revenue share arrangement ~ ~ Rani to host conference call today at 8:00 a.m. ET/5:00 a.m. PT ~ SAN JOSE, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”)(Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a definitive agreement with ProGen Co., Ltd. (“ProGen”)(Konex: 296160), a South Korean clinical-stage biotech company developing next generation long-acting, multi-specific fusion protein therapeutics, for the co-development and commercialization of RT-114, an oral RaniPill® capsule containing ProGen’s PG-102, a GLP-1/GLP-2 dual agonist, for the treatment of obesity. “This collaboration with ProGen reinforces Rani’s clear commitment to improving the lives of people suffering from chronic conditions, such as obesity, by replacing painful injections with the convenience of a pill,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “We chose to collaborate with ProGen based on the potentially unique pharmacokinetic (PK) and tolerability pro PG-102 in a RaniPill® capsule. Given the long half-life of PG-102, the parties intend to pursue development of RT-114 as a convenient, weekly oral dose. It also has the potential to improve body composition and nutritional health of patients owing to the unique mechanism of action of GLP-2. We look forward to working with ProGen to advance RT-114 with the goal of creating a truly differentiated oral anti-obesity medicine designed to enhance patients’ adherence and maximize therapeutic effects with bioavailability comparable to subcutaneous injections.” “This partnership brings together Rani’s oral biologics delivery expertise with ProGen’s two decades of experience in Fc-fusion proteins to enable development of a potentially unique oral therapy option for people with obesity,” said Dr. Jong-Gyun Kim, Chief Executive Officer of ProGen. “Together, we are focused on pursuing RT-114 as a potential first-in-class, oral dual agonist in the anti-obesity arena.” Under the terms of the collaboration agreement, Rani and ProGen agree to share responsibilities for the development and commercialization of RT-114 worldwide, including a 50/50 cost and revenue share arrangement. Rani has exclusive rights to lead development and commercialization of RT-114 in the United States, Europe, Canada and Australia, and ProGen has exclusive rights to lead development and commercialization in the rest of the world. Each party has certain rights to sublicense in its territories. Rani is designated to lead operationally in conducting preclinical and development activities through the Phase 1 program, which is expected to initiate in 2025. As part of this agreement, there is no upfront payment or financial exchange between the companies. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has tested 15 molecules in the RaniPill® platform. The RaniPill® platform has delivered antibodies, peptides and large proteins with high bioavailability. To date, Rani has completed three Phase 1 clinical studies with the RaniPill® capsule. Additionally, ProGen’s preclinical studies demonstrated that treatment with PG-102 resulted in greater glycemic control while inducing a similar degree of body weight loss versus semaglutide and tirzepatide.1 ProGen recently presented results from its Phase 1 single-ascending dose study of PG-102, a GLP-1/GLP-2 dual agonist, at the 2024 American Diabetes Association conference in which PG-102 showed a favorable safety pro lower frequencies of gastrointestinal (GI) side effects compared to competitors’ trials in similar settings. Additionally, the PK/pharmacodynamic (PD) data from this trial and preclinical studies support potential dosing of RT-114 on a weekly to monthly schedule, which could improve patient compliance. Conference Call Rani will host a corresponding conference call and live webcast on June 24, 2024, at 8:00 a.m. ET/5:00 a.m. PT to discuss the ProGen collaboration. Individuals interested in listening to the live conference call may do so by using the webcast link in the “Investors” section of the Company’s website at . A webcast replay will be available in the investor relations section on the Company’s website for 90 days following the completion of the call. About Rani Therapeutics Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com. About ProGen ProGen is a South Korean clinical-stage biotech company developing next generation long-acting biologics for the treatment of metabolic diseases (obesity, type 2 diabetes, etc.) and immune-mediated diseases (inflammatory diseases and cancer). ProGen harnesses its proprietary technology platform known as Neo Tri-ImmunoGlobulin (NTIG®) that enables multi-targeting and allows drugs to have longer in vivo persistence than conventional Fc-fusion proteins. ProGen is currently focusing on the development of its lead product PG-102, a GLP-1/GLP-2-NTIG® fusion protein for the treatment of obesity and type 2 diabetes. PG-102 has shown improvement of body composition and glycemic control compared to tirzepatide in mouse models of obesity with and without type 2 diabetes.2 PG-102 is currently being investigated in a Phase 1b multiple ascending dose trial in Korea. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the potential for RT-114 to be an oral treatment for obesity, the potential for RT-114 to be dosed weekly or less frequently, the potential for RT-114 to have a unique and differentiated product profile, success of the collaboration with ProGen and related activities, and the potential for Rani to make oral biologics a reality for millions of patients living with chronic conditions. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believe,” “design,” “intend,” “look forward,” “could,” “plan,” “goal,” “potential,” “will,” “would” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rani’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rani’s business in general and the other risks described in Rani’s filings with the Securities and Exchange Commission, including Rani’s annual report on Form 10-K for the year ended December 31, 2023, and subsequent filings and reports by Rani. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Rani undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Investor Contact: investors@ranitherapeutics.com Media Contact: media@ranitherapeutics.com 1PG-102, Next Generation GLP-1/GLP-2 Dual Agonist for the Treatment of Metabolic Diseases. Presentation at 2024 BIO Korea 2 Fat-specific weight loss in diet-induced obesity mouse model when treated with bispecific GLP-1R/GLP-2R agonist vs. dual GLP1R/GIPR agonist. Presentation at 59th EASD Annual Meeting

临床1期引进/卖出临床结果

2023-10-25

·PRNewswire

PCR System for Food Diagnostics Market size to grow by USD 977.11 million from 2021 to 2026, North America to account for 41% of market growth- Technavio

NEW YORK, Oct. 25, 2023 /PRNewswire/ -- The PCR system for food diagnostics market is expected to grow by USD 977.11 million from 2021 to 2026. In addition, the momentum of the market will progress at a CAGR of 8.31% during the forecast period, according to Technavio Research. The market has been segmented by Product (consumables and instruments) and Geography (North America, Europe, Asia, and the Rest of the World (ROW)). 41% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets in the region. The presence of several regulatory organizations in the countries will facilitate market growth. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read PDF Sample Report Continue Reading Technavio has announced its latest market research report titled Global PCR System for Food Diagnostics Market 2022-2026 Company Profile: Agilent Technologies Inc., Bio Rad Laboratories Inc., bioMerieux SA, BIOTECON Diagnostics GmbH, F. Hoffmann La Roche Ltd., Generon SpA, Genesystem, Hygiena LLC, Lumex Instruments, LuminUltra Technologies Ltd, Merck and Co. Inc., Microsynth AG, Minerva Biolabs GmbH, Molbio Diagnostics Pvt. Ltd., Mylab Discovery Solutions Pvt Ltd., QIAGEN NV, QuantuMDx Group Ltd., R Biopharm AG, SAN Group GmbH, Xiamen Zeesan Biotech Co. Ltd, and Thermo Fisher Scientific Inc. Agilent Technologies Inc. - The company offers Maxi pads that are biodegradable, chemical-free, and colorful with hooks at the end of the wings to attach to the garment. To gain access to more company profiles available with Technavio, buy the report! PCR System For Food Diagnostics Market: Segmentation Analysis The market share growth by the consumables segment will be significant during the forecast period. Assays, probes, reagents, and kits are included in consumables. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report "Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio PCR System For Food Diagnostics Market: Driver & Trend: Rising foodborne illnesses Organizations advocating food safety globally Increasing food safety regulations globally The rising number of foodborne illnesses is a key factor driving market growth. Most of the foodstuffs consumed are mainly plant or animal-based foods and usually have a wide variety of bacterial species in them. Consequently, companies are focused on minimizing financial losses when unsafe or potentially deadly food products are introduced into the market. Increasing consumer awareness about food safety is a major trend in the market. Identify key trends, drivers, and challenges in the market. Download to gain access to this information. Related Reports: The Food Safety Testing Market is estimated to grow by USD 9,209.62 million between 2022 and 2027 accelerating at a CAGR of 7.84% during the forecast period. The laboratory water purifier market is estimated to grow at a CAGR of 6.86% between 2022 and 2027. The market size is forecast to increase by USD 7,663.32 million. What are the key data covered in this PCR system for Food Diagnostics Market Report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the PCR system for food diagnostics market between 2021 and 2026. Precise estimation of the PCR system for food diagnostics market size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the PCR system for food diagnostics market in North America, Europe, Asia, and ROW A thorough analysis of the market's competitive landscape and detailed information about companies Comprehensive analysis of factors that will challenge the growth of PCR system for food diagnostics market companies. ToC: Executive Summary Market Landscape Market Sizing Historic Market Sizes Five Forces Analysis Market Segmentation by Product Market Segmentation by Geography Customer Landscape Geographic Landscape Drivers, Challenges, & Trends Company Landscape Company Analysis Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio